A Phase 3 interventional study of bempedoic acid and placebo in Hypercholesterolemia and Atherosclerotic Cardiovascular Disease, sponsored by Esperion Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-27.
Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 3rd largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 9th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 779 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one is the 3rd largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 3, and was the 9th registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
bempedoic acid 180 mg/day
Drug: bempedoic acid
Placebo control
Drug: placebo
bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Also known as: ETC-1002
Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Also known as: placebo control
Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)
Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (atherosclerotic cardiovascular diseases \[ASCVD\] and heterozygous familial hypercholesterolemia \[HeFH\]) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 12 are imputed using multiple imputation method taking into account adherence to treatment.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 24 in LDL-C
Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 24 were imputed using multiple imputation method taking into account adherence to treatment.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Baseline is defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing non-HDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
Baseline is defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing TC data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in Apolipoprotein b (Apo B)
Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing apo B data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.
Time frame: Baseline; Week 12
Change From Baseline to Week 12 in LDL-C
Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.
Time frame: Baseline; Week 12
Change From Baseline to Week 24 in LDL-C
Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 12 in Triglycerides (TGs)
Baseline is defined as the mean of the TG values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TG was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in HDL-C
Baseline is defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 52 in LDL-C
Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
Time frame: Baseline; Week 52
Percent Change From Baseline to Week 24 in Non-HDL-C
Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 52 in Non-HDL-C
Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
Time frame: Baseline; Week 52
Percent Change From Baseline to Week 24 in TC
Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 52 in TC
Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
Time frame: Baseline; Week 52
Percent Change From Baseline to Week 24 in Apo B
Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 52 in Apo B
Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
Time frame: Baseline; Week 52
Percent Change From Baseline to Week 24 in hsCRP
Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 52 in hsCRP
Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.
Time frame: Baseline; Week 52
Change From Baseline to Week 52 in LDL-C
Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data. Change from Baseline in LDL-C was analyzed using an ANCOVA model with change from baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and baseline as a covariate.
Time frame: Baseline; Week 52
A total of 779 participants were randomized 2:1 to receive either bempedoic acid or placebo.
| Milestone | Placebo | Bempedoic Acid |
|---|---|---|
| Started | 257 | 522 |
| Completed | 250 | 490 |
| Not completed | 7 | 32 |
| Withdrew: Death | 3 | 8 |
| Withdrew: Protocol violation | 0 | 3 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Moved out of the country | 0 | 1 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 7 |
| Withdrew: Could not attend study visits | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 9 |
Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (atherosclerotic cardiovascular diseases \[ASCVD\] and heterozygous familial hypercholesterolemia \[HeFH\]) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 12 are imputed using multiple imputation method taking into account adherence to treatment.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) | 2.35 ± 1.446 | -15.07 ± 1.073 |
Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 24 were imputed using multiple imputation method taking into account adherence to treatment.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in LDL-C | 2.66 ± 1.910 | -12.10 ± 1.479 |
Baseline is defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing non-HDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | 2.28 ± 1.351 | -10.75 ± 0.952 |
Baseline is defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing TC data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Total Cholesterol (TC) | 1.26 ± 1.010 | -9.94 ± 0.688 |
Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing apo B data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Apolipoprotein b (Apo B) | 3.73 ± 1.340 | -9.29 ± 0.851 |
Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP) | -9.366 (-36.320 to 35.241) | -18.699 (-46.067 to 23.864) |
Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.
| mg/dL | Placebo | Bempedoic Acid |
|---|---|---|
| Change From Baseline to Week 12 in LDL-C | 0.0 ± 30.62 | -21.2 ± 30.82 |
Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.
| mg/dL | Placebo | Bempedoic Acid |
|---|---|---|
| Change From Baseline to Week 24 in LDL-C | -1.0 ± 37.51 | -18.7 ± 35.76 |
Baseline is defined as the mean of the TG values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TG was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Triglycerides (TGs) | 6.12 ± 2.294 | 11.01 ± 2.312 |
Baseline is defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in HDL-C | -0.25 ± 0.864 | -6.38 ± 0.741 |
Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in LDL-C | -0.97 ± 1.830 | -13.24 ± 1.412 |
Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in Non-HDL-C | 2.44 ± 1.611 | -10.19 ± 1.200 |
Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in Non-HDL-C | -0.42 ± 1.605 | -10.34 ± 1.150 |
Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in TC | 1.52 ± 1.216 | -9.25 ± 0.857 |
Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in TC | -1.89 ± 1.199 | -10.25 ± 0.828 |
Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in Apo B | 4.39 ± 2.090 | -8.61 ± 1.267 |
Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in Apo B | 3.01 ± 1.502 | -6.56 ± 0.983 |
Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in hsCRP | 1.563 (-32.174 to 47.500) | -24.107 (-51.502 to 14.035) |
Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in hsCRP | -6.250 (-39.286 to 41.810) | -16.727 (-50.877 to 31.429) |
Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data. Change from Baseline in LDL-C was analyzed using an ANCOVA model with change from baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and baseline as a covariate.
| mg/dL | Placebo | Bempedoic Acid |
|---|---|---|
| Change From Baseline to Week 52 in LDL-C | -4.71 ± 2.216 | -19.78 ± 1.433 |
Collected over up to Week 52. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/257 (0.8%) | 48/257 (18.7%) | 88/257 (34.2%) |
| Bempedoic Acid | 6/522 (1.1%) | 106/522 (20.3%) | 211/522 (40.4%) |
| Event | Placebo | Bempedoic Acid |
|---|---|---|
| Angina unstableCardiac disorders | 6/257 | 9/522 |
| Coronary artery diseaseCardiac disorders | 6/257 | 7/522 |
| Angina pectorisCardiac disorders | 1/257 | 12/522 |
| Myocardial ischaemiaCardiac disorders | 4/257 | 2/522 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/257 | 0/522 |
| Acute myocardial infarctionCardiac disorders | 3/257 | 2/522 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/257 | 5/522 |
| Cardiac arrestCardiac disorders | 2/257 | 2/522 |
| Cardiac failureCardiac disorders | 2/257 | 0/522 |
| Myocardial infarctionCardiac disorders | 2/257 | 2/522 |
| Event | Placebo | Bempedoic Acid |
|---|---|---|
| NasopharyngitisInfections and infestations | 13/257 | 27/522 |
| Urinary tract infectionInfections and infestations | 5/257 | 24/522 |
| HyperuricaemiaMetabolism and nutrition disorders | 5/257 | 22/522 |
| Upper respiratory tract infectionInfections and infestations | 9/257 | 19/522 |
| FatigueGeneral disorders | 9/257 | 6/522 |
| DizzinessNervous system disorders | 9/257 | 8/522 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/257 | 18/522 |
| MyalgiaMusculoskeletal and connective tissue disorders | 8/257 | 15/522 |
| DiarrhoeaGastrointestinal disorders | 7/257 | 16/522 |
| Lower respiratory tract infectionInfections and infestations | 7/257 | 7/522 |
| Age, Continuous(years) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 64.7 ± 8.73 | 64.1 ± 8.82 | 64.3 ± 8.79 |
| Sex: Female, Male(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Female | 89 | 194 | 283 |
| Male | 168 | 328 | 496 |
| Race/Ethnicity, Customized(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 4 | 4 |
| Black or African American | 12 | 24 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 244 | 491 | 735 |
| Multiple | 0 | 2 | 2 |
| Mean low-density lipoprotein cholesterol (LDL-C)(milligrams per deciliter (mg/dL)) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 122.4 ± 38.30 | 119.4 ± 37.75 | 120.43 ± 37.931 |
| LDL-C category(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| <130 mg/dL | 173 | 365 | 538 |
| ≥130 and <160 mg/dL | 45 | 89 | 134 |
| ≥160 mg/dL | 39 | 68 | 107 |
| Mean non-high-density lipoprotein cholesterol (non-HDL-C)(mg/dL) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 153.7 ± 44.36 | 150.7 ± 42.75 | 151.7 ± 43.28 |
| Mean total cholesterol (TC)(mg/dL) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 204.8 ± 46.06 | 202.1 ± 42.71 | 203.0 ± 43.83 |
| Mean apolipoprotein B (apoB)(mg/dL) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 118.6 ± 30.53 | 116.2 ± 29.58 | 117.0 ± 29.90 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Aug 2018, 21 months.
Results were first posted in Apr 2020, 1 year 8 months after primary completion. A results delay was requested in Nov 2018.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid